- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02263651
Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage (QUISERMAS)
Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage in Prevention of Seroma Formation After Mastectomy for Breast Cancer : a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible patients are patients with operable breast cancer (invasive carcinoma and/or carcinoma in situ) for whom mastectomy is recommended or preferred by the patient either alone or in association with sentinel lymph node biopsy or standard level I/II axillary node dissection
Randomization will be stratified by center and by type of surgery (mastectomy alone/ mastectomy with sentinel node biopsy / mastectomy with axillary lymph node dissection).
Two follow-up visits will be performed: at 21 days and 9 months after surgery, these appointments are conventional, thus our trial will not modify usual follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13005
- Conception hospital
-
Marseille, France, 13009
- Institut POALI-CALMETTES
-
Nantes, France
- Institut de Cancérologie de l'Ouest
-
Poitiers, France
- CHU de Poitiers
-
St Cyr sur Loire, France
- Alliance Clinic
-
Tours, France
- CHRU de Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women ≥ 18 years and ≤ 85 years
- Women with operable breast cancer (invasive carcinoma and/or carcinoma in situ) for whom mastectomy is recommended or preferred by the patient either alone or in association with sentinel lymph node biopsy or standard level I/II axillary node dissection
- Women that give her informed written consent
- French social security affiliation
Exclusion Criteria:
- Any physical or psychiatric condition that could impair with patient's ability to cooperate with postoperative data collection.
- Women with indication of bilateral mastectomy or immediate reconstruction.
- Degenerative neuromuscular disease with thoracic muscular damage
- Planned ambulatory surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Closure with conventional technique with drainage
The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area.
The drain is stitched to the skin.
|
The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin. The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent.
Other Names:
|
|
Experimental: Quilting suture without drainage
In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent).
Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle.
|
In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced. Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex. The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound seroma requiring aspiration or surgical intervention
Time Frame: Within 21 days following mastectomy
|
A seroma is defined as a postoperative fluid collection via palpation on clinical examination. The Common Terminology Criteria for Adverse Events (CTCAE) which is a descriptive terminology that can be used for adverse event reporting provide a grading scale for seromas (lymphoceles). Only grade 2 and 3 seromas i.e. seromas requiring one or more aspirations or a surgical intervention will be considered as primary outcome. |
Within 21 days following mastectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound seroma requiring aspiration or surgical intervention
Time Frame: Within 9 months following mastectomy
|
Within 9 months following mastectomy
|
|
|
Wound seroma whatever their type (requiring or not intervention)
Time Frame: Within 21 days following mastectomy
|
Within 21 days following mastectomy
|
|
|
Wound seroma whatever their type (requiring or not intervention)
Time Frame: Within 9 months following mastectomy
|
Within 9 months following mastectomy
|
|
|
Other wound complications
Time Frame: Within 21 days following mastectomy
|
Within 21 days following mastectomy
|
|
|
Other wound complications
Time Frame: Within 9 months following mastectomy
|
Within 9 months following mastectomy
|
|
|
Surgical morbidity
Time Frame: During surgical intervention
|
During surgical intervention
|
|
|
Pain
Time Frame: Before surgery, day 1, 21 days and 9 months following mastectomy
|
Visual Analogue Scale
|
Before surgery, day 1, 21 days and 9 months following mastectomy
|
|
Homolateral shoulder movement
Time Frame: Before surgery, 21 days and 9 months following mastectomy
|
The range of arm movement scored from 1 to 4 according to estimated angles of arm abduction as 1 (less than 90°), 2 (90-134°), 3 (135-179°) and 4 (180°)
|
Before surgery, 21 days and 9 months following mastectomy
|
|
Cosmesis results
Time Frame: 21 days, 9 months following mastectomy
|
Cosmetic results will be documented by patient,surgeon and by an blinded adjudication committee with possible response = poor, acceptable, good and excellent
|
21 days, 9 months following mastectomy
|
|
Health related quality of life : EQ-5D-5L
Time Frame: Before surgery, day 1, 21 days and 9 months following mastectomy
|
The descriptive system comprises 5 dimensions : mobility, self care, usual activities, pain/discomfort, anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems
|
Before surgery, day 1, 21 days and 9 months following mastectomy
|
|
Cost-effectiveness assessment
Time Frame: During the whole follow-up period i.e. 9 months following mastectomy
|
Incremental net monetary benefice
|
During the whole follow-up period i.e. 9 months following mastectomy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lobna OULDAMER, MD, University Hospital, Tours
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHRCK13 - LO / QUISERMAS
- 2014-A00901-46 (Other Identifier: ID RCB)
- 140730B-12 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.